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Abstract
Introduction: Global scale up of anti-retroviral therapy (ART) has led to expansion of HIV treatment and prevention across
sub-Saharan Africa. However, age and gender-specific disparities persist leading to failures in fulfillment of Sustainability Devel-
opment Goals, including SDG3 (achieving healthy lives and wellbeing for all, at all ages) and SDG5 (gender equality). We
assessed ART initiation and adherence, loss to follow-up, all-cause death and early death, according to SDG3 and SDG5 indica-
tors among a cohort of HIV-infected children and adolescents enrolled in care in Dar-es-Salaam, Tanzania
Methods: SDG3 indicators included young (<5 years) and older paediatric children (5 to <10 years), early adolescent (10 to
<15 years) and late adolescent (15 to <20 years) age group divisions and the SDG5 indicator was gender. Associations of age
group and gender with ART initiation, loss to follow-up and all-cause death, were analysed using Cox proportional hazards
regression and with adherence, using generalized estimating equations (GEE) with the Poisson distribution. Associations of age
group and gender with early death were analysed, using log-Poisson regression with empirical variance.
Results: A total of 18,315 enrollees with at least one clinic visit were included in this cohort study. Of these 7238 (40%) were
young paediatric , 4169 (23%) older paediatric, 2922 (16%) early adolescent and 3986 (22%) late adolescent patients at enrol-
ment. Just over half of paediatric and early adolescents and around four fifths of the late adolescents were female. Young pae-
diatric patients were at greater risk of early death, being almost twice as likely to die within 90 days. Males were at greater
risk of early death once initiated on ART (HR 1.35, 95% CI 1.09, 1.66)), while females in late adolescence were at greatest risk
of late death (HR 2.44 [1.60, 3.74] <0.01). Late adolescents demonstrated greater non-engagement in care (RR 1.21 (95% CI
1.16, 1.26)). Among both males and females, early paediatric and late adolescent groups experienced significantly greater loss
to follow-up.
Conclusion: These findings highlight equity concerns critical to the fulfillment of SDG3 and SDG5 within services for children
and adolescents living with HIV in sub-Saharan Africa. Young paediatric and late adolescent age groups were at increased risk
of late diagnosis, early death, delayed treatment initiation and loss of continuity of care. Males were more likely to die earlier.
Special attention to SDG3 and SDG5 disparities for children and adolescents living with HIV will be critical for fulfillment of
the 2030 SDG agenda.
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1 | INTRODUCTION
Global expansion of anti-retroviral therapy (ART) has led to
the marked success of prevention of mother-to-child transmis-
sion (PMTCT) programmes and increased enrolment into HIV
care programmes across sub-Saharan Africa [1]. Despite signif-
icant strides in PMTCT globally, significant age and gender
disparities exist in outcomes of efforts to prevent, diagnose,
treat and manage HIV among children and adolescents, with
significant implications for the fulfillment of SDG3 (achieving
healthy lives and wellbeing for all, at all ages) and SDG5 (gen-
der equality). Children are particularly vulnerable, experiencing
a wide array of challenges, ranging from barriers to testing
and treatment, to failures in continuity of care [1]. Not all
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mothers receive antiretroviral medicines (ARVs), and delays in
newborn testing and treatment persist with effects on
perinatal transmission and disease management [2,3]. Global
disparities in HIV-related child mortality continue to dispro-
portionately burden sub-Saharan Africa [4]. While global
reductions in HIV-related mortality have largely been driven
by successful treatment of infections across other age groups,
HIV-related deaths among adolescents, particularly among
girls, have risen during the same period [5,6]. Within the sub-
Saharan African HIV epidemic, adolescent girls are known to
experience higher incidence of infections and barriers to care
in late adolescence [7], while males experience relatively
higher mortality [8,9]. Failure to address the age and gender-
specific needs of children and adolescents infected with HIV
in sub-Saharan Africa leads to failure to fulfill SDG3 and
SDG5, with further interdependent failings in several Sustain-
ability Development Goals (SDGs) [10].
The SDGs provide scope for the unification of development
efforts across different sectors in the fulfillment of a single
agenda for health [11]. Arguably health is central to the
fulfillment of the SDGs, being both as essential precursor and
consequence of sustainable development [12]. Integrating
framework approaches can incorporate multiple SDG targets
and provide opportunity for intersectoral and coordinated
action for health [12]. To achieve health for all children living
with HIV in sub-Saharan Africa, an integrated approach may
strengthen links between targets within SDG3, such as SDG
3.3 (to end the AIDS and TB epidemics), 3.7 (sexual and
reproductive health) and 3.8 (universal health coverage) and
also strengthen links across different sectors. For instance,
links between SDG3 and SD4 (education) targets, such as
SDG 4.1 to 4.7, may emphasize relationships between child
and adolescent sexual health and primary and secondary edu-
cation. Links with SDG8 (economic productivity) targets 8.1 to
8.6 may facilitate measurement of the impacts of child and
adolescent HIV on varying dimensions of the economic growth
within the nation. An integrating framework approach can map
differences in progress across all of the implicated sectors
according to gender (to highlight progress towards SDG5) and
according to international standards (to highlight progress
towards SDG10 (reducing inequality within and among coun-
tries)) [8-16]. Through mapping and measuring progress across
the multiple sectors implicated by the HIV epidemic among
children and adolescents, greater progress towards SDG17
may also be achieved, driving improvements in data required
for greater accountability. Failure to achieve gender and age
equity within the control of the African HIV epidemic, would
lead to the failure of multiple interrelated SDG targets and
objectives.
Shortfalls in approaches to HIV treatment and care and
attendant age and gender-specific disparities in treatment,
health outcomes, and continuity of care within the health ser-
vices of sub-Saharan African countries have been increasingly
well described over the past several years [8,9,13-19]. This
establishes a precedent for greater measurement of the
impacts of these deficits on fulfillment of the SDGs as we
move towards 2030. Tracking progress within an integrating
SDG framework would allow for better capture of the inter-
linked impacts of child and adolescent health on varying
aspects of sustainable development. Better monitoring and
evaluation of progress towards 2030 goals additionally
highlight novel intersectoral opportunities for intervention.
Current efforts to track progress in delivering health for chil-
dren and adolescents living with HIV largely rely on the
UNAIDS 90-90-90 targets [20]. Integrating UNAIDS 90-90-
90 targets within an SDG framework would also shed light on
opportunities to improve the health of children and adoles-
cents living with HIV through intersectoral approaches [20].
Continued engagement with existing services is critical to
the care of children living with HIV. Non-engagement and loss
to follow-up are important indicators of failure in continuity of
care [18,19,21]. Although there is no singular gold standard
measure to describe the varying forms of non-engagement in
care, non-attendance has been described as a useful indicator
of non-engagement within this setting [19]. Non-engagement
in care is associated with worse health outcomes among HIV-
infected patients [21]. It is important to further understand
the varying failures in the continuity of care of HIV-positive
children and adolescents enroled in services in high disease
prevalence and impoverished settings [21]. This prospective
cohort study assesses early death and late all-cause death,
ART initiation, non-attendance as a form of non-engagement
in care and loss to follow-up. Utilizing SDG3 and SDG5 age
and gender-specific indicators, we sought to assess disparities
in access to treatment, continuity of care and outcomes,
among children and adolescents enrolled in a large sub-
Saharan African HIV care service in Tanzania.
2 | METHODS
2.1 | Study population
The cohort included all HIV-infected patients who were under
20 years of age at enrolment in services, between October
2004 and September 2014, within the urban HIV care and
treatment clinics of Dar-es-Salaam, Tanzania (supported by
Management and Development for Health (MDH) and the US
President’s Emergency Plan for AIDS relief (PEPFAR)). At the
beginning of the study period the study catchment area
included 28 clinics, which grew to 48 clinics by the end of the
study period. Patients under the age of 15 years were consid-
ered paediatric for treatment purposes. The year of MDH
enrolment was categorized, to reflect changes in Tanzanian
National AIDS Control Program treatment guidelines, as 2004
to 2007, 2008 to 2011, and 2012 to 2014. Verbal consent
for inclusion within research activities within the clinical pro-
gramme was obtained from parents of children or from those
patients over the age of 16 years, at enrolment, as appropri-
ate. The Harvard TH Chan School of Public Health and
Muhimbili University of Health and Allied Sciences Institu-
tional Review Boards gave ethical clearance for this study
(IRB 17-1998).
2.2 | Patient assessments, ART and follow-up visits
plan
All participants received free routine care and treatment for
HIV according to Tanzanian National AIDS Control Program
(NACP) Ministry of Health and Social Welfare guidelines,
approved by the World Health Organization (WHO). Patients
eligible for ART received free ART provision, subsidized by the
Tanzanian government. Patients on ART were followed every
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28 days for repeat physician assessment, refill of ART medica-
tion and counseling to discuss adherence, dosing and drug side
effects. Late adolescent patients, who did not receive ART
received supportive care and regular assessment of their eligi-
bility for ART initiation every 6 months. Pediatric patients on
care were reviewed monthly if under 5 years of age, or were
reviewed every 3 months if above 5 years of age. ART initia-
tion criteria differed by CD4 count percentage, age and period
of enrolment. Before 2008, ART was initiated regardless of
CD4 count percentage for children who were at WHO disease
stage III/IV; for children with WHO stage I/II disease, ART was
initiated if CD4 was below age-adjusted thresholds (for those
who were 12 to 18 months of age when CD4+ % was less
than 25; between 19 and 59 months of age when CD4+ %
was below 20; and for children 5 years of age and above when
CD4+ % was below 15 (or CD4+ cell count <200 cells/ml)).
For those <12 months of age, criteria changed in 2008. After
2008, ART was initiated if CD4+ % was <25 for those at
WHO stage I/II and for all children who were <12 months of
age, regardless of CD4+ % or WHO stage. Patients age 15 or
older were treated by adult criteria. Weight and height were
recorded at each visit. Data on ART and TB treatment, preg-
nancy and next appointment date were collected at each visit
and laboratory measurements, and CD4 counts were per-
formed and recorded every 6 months.
2.3 | Definition of outcomes
Person-time was divided between time “pre-ART” and time “on
ART”. Patients whose time of follow-up coincided with their
time to ART initiation were considered pre-ART, as they had
no follow-up on ART. For both types of person-time we con-
sidered 3 outcomes: “early death” (all cause death within
90 days of the beginning of that type of person-time), ‘late
death’ (all-cause death more than 90 days after the beginning
of that type of person-time), “loss to follow-up” (for pre-ART
patients, this means that the time to death or the study cutoff
date was more than 180 days later than the scheduled
appointment at their last recorded visit, or if there was no
scheduled appointment recorded, more than 240 days later
than their last visit). Patients on ART were considered lost to
follow-up, if time to death or the study cutoff date was more
than 190 days after the scheduled appointment at their last
recorded visit, or if there was no scheduled appointment
recorded, more than 120 days later than their last visit. In
addition, among patients on care, we considered the outcome
of “ART initiation”. Among patients on ART, we considered the
outcome of “non-engagement in care”, defined as being 20%
of the interval between visits later than the date of the sched-
uled appointment.
2.4 | Data collection
Standardized forms were completed at each visit to detail clin-
ical information. Standardized procedures for the measure-
ment of height and weight were in place to record these at
each clinic visit. Blood samples were taken at registration and
every 6 months thereafter for hematologic, biochemical and
immunologic profiling. Data assurance processes were in place
at the point of entry including review checks, double data
entry and supervisory checks for inconsistencies identified on
second entry. Furthermore, weekly quality assurance checks of
data were in place.
2.5 | Statistical analysis
Primary determinants in the analysis included SDG3 and
SDG5 indicators, generated through categorizing patients into
five-year age groups (0 to <5 young paediatric patients, 5 to
<10 older paediatric patients, 10 to <15 early adolescent, 15
to <20 late adolescent) and according to gender, to compare
intragroup differences in outcomes to assess equity. All analy-
ses were undertaken separately among pre-ART and on ART
patients. Baseline characteristics were examined for the young
and older paediatric, early and late adolescent age group, as
well as gender groups. Means and standard deviations or
medians with interquartile ranges were used to describe the
centrality and distribution of continuous measurements and
proportions to describe categorical measurements of baseline
characteristics. Baseline covariates including WHO stage and
immunodeficiency for age, HIV wasting syndrome (defined as
at least 10% weight loss if the patient had diarrhoea and
chronic weight loss and documented fever for at least 30 days
not attributable to any concurrent condition), TB treatment,
year of first clinic visit, district of clinic and marital and preg-
nancy status (for older adolescents). Immunodeficiency for age
categories were constructed (with CD4 percent intervals cut
at 25%, 30% and 35% for children <11 months of age, at
20%, 25% and 30% for children aged between 12 and
35 months and at 15%, 20% and 25% for children aged
between 36 and 59 months with CD4 count intervals cut at
15% or 200, 350 and 500 cells/mm3 for children older than
5 years of age) in keeping with 2007 WHO guidelines [19].
Age-specific weight-for-length and BMI z-scores were catego-
rized at z-scores of 3 and 2, categorized as severely mal-
nourished (z-score <3), malnourished (z-score ≥3 by <2),
and not malnourished (z-score ≥2) (using weight-for-length
z-scores for children under 5 years of age and BMI z-score
for patients 5 years of age and over). The year of MDH enrol-
ment was categorized, roughly coinciding with changes in the
treatment guidelines of the Tanzanian National AIDS Control
Program, as 2004 to 2007, 2008 to 2011, and 2012 to 2014.
Missing indicators were created as necessary. For continuous
variables the median value was imputed.
Crude rates and their 95% confidence intervals were deter-
mined using Poisson regression. Relative risks (RR) and 95%
confidence intervals (CI) for early death were determined using
generalized estimating equations (GEE) with the log link and the
Poisson distribution to approximate log-binomial regression
[18]. Associations of age group and gender with late death, ART
initiation and loss-to-follow-up were analysed, using Cox pro-
portional hazards regression. Age group and gender associa-
tions with non-attendance were examined with generalized
estimating equations (GEE) with the log link and Poisson distri-
bution for repeated measures of patient visits, using a com-
pound symmetry working correlation and the robust variance.
Hazard ratios (HR) for receiving a prescription for ART
were determined using proportional hazards models, adjusted
for death and loss to follow-up, using inverse probability
weighting. Relative risks (RR) and 95% confidence intervals
(CI) for non-engagement in care were determined using GEE
models with the log link, the Poisson distribution, and the
Chaudhury S et al. Journal of the International AIDS Society 2018, 21(S1):e25070
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25070/full | https://doi.org/10.1002/jia2.25070
12
exchangeable working covariance structure [22]. For analyses
using the subset of patients on ART, we also controlled for 4-
knot splines of time to ART initiation.
Given that the central exposures of interest in this study
were baseline values (to include gender and age group at
enrolment), we did not adjust for time-varying covariates. We
controlled for baseline covariates measured at enrolment to
adjust for differences between age and gender groups.
Covariates used included immunodeficiency for age and
WHO HIV clinical stage based on 2007 WHO guidelines [19],
presence of HIV wasting syndrome (as determined by the
evaluating clinician), treatment for tuberculosis (TB), weight-
for-height z-scores, weight-for-length z-scores for children
under 5 and BMI z-score for patients 5 and over), catego-
rized as severely malnourished (z-score <3), malnourished
(z-score ≥3 by <2), and not malnourished (z-score ≥2)
and district of Dar es Salaam. Potential confounders were
selected, using a priori knowledge. Adjusted models included
age group, gender, WHO HIV stage, BMI or weight-for-length
z-score (<3, 3 to <2, ≥2), HIV wasting syndrome,
immunodeficiency for age, TB treatment at enrolment, year of
first clinic visit (2004 to 2007, 2008 to 2011, 2012 to 2014)
and district of Dar es Salaam (Ilala, Kinondoni, Temeke). In all
situations where the analysis used a subset of the data (e.g.
late death, on ART), inverse probability weighting was used to
adjust for censoring.
Cumulative incidence curves were constructed, using the
Breslow estimator for multivariate proportional hazards models
and adjusted for the following variables at enrolment: WHO
HIV stage, immunodeficiency for age, HIV wasting syndrome,
BMI or weight-for-length z-score, pregnancy status, year of
enrolment and district. Results were standardized to WHO HIV
stage 1, CD4 high (500+ or 25%+), no HIV wasting syndrome,
BMI or weight-for-length z-score at least 2, not treated for
TB, not pregnant, year 2004 to 2008, Ilala district.
For each outcome, univariate models of age group and gen-
der SDG3 and SDG5 indicators, multivariate adjusted models,
and models including interactions of age group with gender,
were constructed. For proportional hazards models, p-values
for interaction were calculated, using the likelihood ratio test.
For log-Poisson models, p-values for interaction were com-
puted using the robust score test. All statistical tests were
two-sided, and p-values of 0.05 or less were considered statis-
tically significant. If the interactions were significant at the
p = 0.05 level, we reported the results for age group within
gender and for gender within age group. To test for non-pro-
portionality of hazards over time we divided the follow-up
time for each outcome at the mean and introduced two-way
interactions with age and gender. We selected backwards on
these variables, retaining other model variables. No adjust-
ment was made for multiple comparisons. Statistical analysis
was undertaken using SAS 9.3 (Cary, North Carolina, USA).
3 | RESULTS
A total of 18,315 patients who were under 20 at MDH enrol-
ment were included in our data. Of these, 10,790 (59%) were
female, and 7325 (41%) were male. Among the paediatric and
early adolescent patients there were approximately equal num-
bers of girls and boys, but among the late adolescents around
80% were young women. Around a third of the females who
enrolled in late adolescence were pregnant at enrolment
(Table 1).
Median follow-up time (IQR) was 656 (145, 1605) days.
Among all patients, 12,299 (67%) received prescriptions for
ART, including 658 (4% of those who received ART prescrip-
tions) whose last follow-up was the same as the date of the ART
prescription (Table 1). Among pre-ART patients, 331 (2%) had an
early death (within 90 days ofMDH enrolment), 197 a late death
(3% of the 6315 who were followed for more than 90 days on
care) and 5346 were lost to follow-up. Among patients on ART,
365 (3%) had an early death), and 483 (5% of the 10,085 who
were followed for more than 90 days after ART initiation) had a
late death (Table 1 and Table 2). Among those on ART, the med-
ian time from MDH enrolment to ART initiation was 28 days
(IQR (10, 137) days). Among pre-ART patients, the hazard ratios
for receiving a prescription for ART varied jointly by gender and
age (gender-age interaction p < 0.01), with early adolescents
being most likely to receive prescriptions among the girls, but
older paediatric patients being most likely to receive prescrip-
tions among the boys (Table 3). Among late adolescents, males
were much more likely to receive prescriptions than females (HR
1.32; 95% CI 1.21, 1.45). Among pre-ART patients, follow-up
time was related to the effects of both age group and gender on
receiving a prescription for ART. For both females and males, all
age groups were less or approximately equally likely to receive
ART prescriptions than older paediatric patients before the
mean time, but much more likely to receive ART prescriptions
after the mean time.
SDG3 indicators demonstrated that among pre-ART patients,
young paediatric patients were most likely to experience both
early and late death. Risk of early death was highest in pre-ART
patients but remained comparably high among patients on ART.
Follow-up time did not influence the hazard ratios for late
death. SDG3 indicator for late adolescents was most strongly
associated with loss to follow-up, followed by the young paedi-
atric group. Neither SDG3 nor SDG5 indicators were related to
late death. SDG3 was implicated within loss to follow-up, being
greater among young paediatric patients, but higher still for
both genders in late adolescence (Table 3).
Among patients on ART, both SDG3 and SDG5 indicators
were implicated with males, young paediatric and early adoles-
cent patients being more likely to experience early death.
Young paediatric patients were the least likely to be lost to
follow-up. Follow-up time did not influence the hazard ratios
for these outcomes. Among patients on ART, follow-up time
affected the hazard ratios for age group for the late death
outcome, with a halving of the hazard ratio for young paedi-
atric patients relative to older paediatric patients in both gen-
ders after the mean follow-up time. Both before and after the
mean follow-up time, hazard ratios for the other age groups
relative to the older paediatric group were more extreme
among females than among males.
SDG3 indicator for late adolescence was most significantly
implicated with regards to poor engagement in care. For
both genders late adolescents were more likely to be lost to
follow up and non-engaged in care. Among pre-ART patients
SDG 3 and SDG5 indicator interactions were significant for
loss to follow-up and ART initiation, but not among those
patients already on ART for loss to follow up and non-
engagement.
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Figure 1 shows the cumulative incidence of death was gen-
erally more severe among males than females, with highest
cumulative incidence of death being among early adolescent
males. Early adolescents generally experienced the highest
cumulative incidence of death followed by late adolescents,
then paediatric patients (younger, followed by older paediatric
patients, among females (see Figure 1a,c)). (Where there was
suggestion of non-proportionality and the further test for age-
time interaction was significant at the p-value results were
further disaggregated by time and presented in the supporting
information).
Figure 2 shows that the overall hazard ratio for death
according to age at enrollment, was highest shortly after birth,
decreasing sharply until around age 6, and then increasing
into late adolescence, when compared to death at aged
10 years at enrolment. Patients on ART generally experienced
more rapid declines in relative risk of death, than patients on
care, until around 5 years of age at MDH enrolment (see
Figure 2c and 2d)).
4 | DISCUSSION
Current experience of enrollees in HIV care and treatment
programmes across sub-Saharan Africa is being increasingly
well described [7-16]. Both female [3,5], and male [7-9] chil-
dren and adolescents living with HIV experience age and gen-
der-specific inequities in access to and continuity of HIV
treatment and care with significant implications for the fulfill-
ment of SDG3 and SDG5. Given the centrality of health for
all ages and gender equality within the SDG agenda, intersec-
toral opportunities to protect and promote the health of chil-
dren and adolescents living with HIV in sub-Saharan Africa
must be further examined.
It has been well recognized that young children living with
HIV remain vulnerable to shortcomings in testing [2] and link-
age to treatment [3], with potential consequence for their sur-
vival. Our findings corroborate that young paediatric patients
remain particularly vulnerable to early death. Both in terms of
SDG3 and SDG5 indicators, this study highlights that the
young paediatric age group and male gender children are par-
ticularly at risk of early death, even when linked with care.
This may be due to delays in testing or linkage to treatment
once test results are available. Risk of early death was highest
for the pre-ART young children, but remained high among
those on ART. But these findings suggest further measures
must be taken to improve care during early life for these
high-risk groups.
Recent evidence also suggests that adolescents remain vul-
nerable to poor adherence and loss of retention within HIV
Table 2. Crude ratesa of early and late death and loss to follow-up by age group and gender SDG3 and SDG5 indicators
SDG3 and SDG5
indicators
Early death Late death ART initiation Loss to follow-up
Years of
follow-up
Crude rate
[95% CI]/
100 person
years
Years of
follow-up
Crude rate
[95% CI]/
100 person
years
Years of
follow-up
Crude rate
[95% CI]/
100 person
years
Years of
follow-up
Crude rate
[95% CI]/
100 person
years
Patients pre-ART
Female 1327 12.2 [8.6, 17.4] 6038 1.7 [1.2, 2.6] 7293 96.2 [93.9, 98.4] 7363 47.5 [30.6, 73.7]
Young paediatric 2616 18.6 [11.7, 29.5] 2138 2.1 [1.2, 3.8] 2587 89.8 [86.2, 93.5] 2616 51.8 [26.5, 101.4]
Older paediatric 1673 8.8 [3.4, 22.7] 1391 1.8 [0.7, 4.5] 1658 95.0 [90.3, 99.7] 1673 34.9 [11.0, 110.9]
Early adolescent 954 13.2 [6.5, 26.6] 772 1.8 [0.6, 5.5] 944 130.1 [122.9, 137.4] 954 36.4 [9.6, 138.3]
Late adolescent 2120 6.2 [1.9, 20.1] 1736 1.2 [0.5, 2.7] 2103 89.6 [85.5, 93.6] 2120 57.0 [26.4, 123.4]
Male 4592 19.1 [13.6, 26.7] 3707 2.5 [1.5, 4.1] 4543 116.3 [113.2, 119.5] 4592 24.4 [24.4, 72.9]
Young paediatric 2070 24.2 [15.2, 38.3] 1649 3.0 [1.4, 6.4] 2041 107.3 [102.8, 111.8] 2070 54.5 [26.9, 110.2]
Older paediatric 1445 12.0 [5.3, 27.2] 1211 1.4 [0.6, 6.4] 1438 98.6 [93.5, 103.8] 1444 28.7 [7.9, 104.0]
Early adolescent 777 15.2 [7.6, 30.4] 626 2.6 [0.7, 9.2] 772 134.3 [126.2, 142.5] 777 28.5 [6.0, 135.4]
Late adolescent 300 20.4 [7.1, 58.4] 222 4.5 [2.4, 8.6] 292 218.8 [201.9, 235.8] 300 58.2 [12.3, 276.1]
Patients on ART
Female 1497 11.6 [8.3, 16.3] 15,343 1.7 [1.0, 2.9] — — 16,480 17.3 [15.6 19.2]
Young paediatric 496 16.7 [10.6, 26.4] 5375 1.8 [0.7, 4.6] — — 5871 17.2 [14.1, 20.9]
Older paediatric 355 6.5 [2.0, 20.5] 6021 0.9 [0.4, 2.2] — — 4659 15.3 [12.4, 18.9]
Early adolescent 278 9.5 [5.6, 25.4] 3189 1.7 [0.4, 7.6] — — 3467 16.0 [13.2, 19.3]
Late adolescent 368 8.4 [4.4, 20.7] 2475 2.7 [1.1, 6.6] — — 2844 22.6 [18.4, 27.9]
Male 1161 16.4 [11.1, 24.3] 13,358 1.7 [1.0, 2.9] — — 14,519 16.6 [14.9, 18.6]
Young paediatric 474 19.4 [10.6, 35.5] 5362 1.5 [0.7, 3.1] — — 5836 17.0 [14.2, 20.4]
Older paediatric 322 10.3 [4.7, 22.4] 4033 1.4 [0.4, 4.2] — — 4355 15.8 [13.2, 19.0]
Early adolescent 232 15.5 [7.8, 30.8] 2832 2.1 [0.6, 7.4] — — 3064 15.7 [12.0, 20.5]
Late adolescent 133 22.5 [7.5, 68.1] 1131 2.7 [0.7, 10.8] — — 1264 20.2 [14.2, 28.9]
a
Crude rates computed by Poisson regression. N.B. Person-years may not add to totals because of rounding errors.
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Figure 1. Adjusted cumulative incidence of death by Age Group and Gender SDG3 and SDG5 indicators. (a) Cumulative incidence of late
death among females pre-ART. (b) Cumulative incidence of late death among males pre-ART. (c) Cumulative incidence of late death among
females on ART. (d) Cumulative incidence of late death among males on ART
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2a. Hazard Raos with 95%CI for Late Death pre-ART 2b. Hazard Raos with 95%CI for Late Death on ART
2c. Relave Risks with 95%CI for Early Death pre-ART 2d. Relave Risks with 95%CI for Early Death on ART
Figure 2. Hazard ratio for death according to age in years at enrolment (relative to rate at Age 10). (a) Hazard ratios with 95% CI for late
death pre-ART. (b) Hazard ratios with 95%CI for late death on ART. (c) Relative risks with 95% CI for early death pre-ART. (d) Relative risks
with 95%CI for early death on ART
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care programmes [14-16]. Our findings further confirm that
the SDG3 indicator of late adolescence was particularly impli-
cated in loss to follow up and poor engagement with care.
SDG3 and SDG5 interactions being significant among the
pre-ART children and adolescents, implies significant age and
gender differences in patterns of engagement with care,
particularly prior to ART initiation. This further supports the
assertion that fulfillment of SDG3 and SDG5 for children liv-
ing with HIV prior to ART initiation depends on age and gen-
der specific strategies to address engagement with care.
SDG 5 indicators were implicated significantly for early
death in our findings. Additionally, crude death rates were the
highest among males, being worst among the younger paedi-
atric patients, reducing among the older paediatric patients,
before worsening with increasing age category into late ado-
lescence. Higher death rates among males may be explained
by later presentation and greater non-enegagement with care
among [14,23,24]. Adolescent males are known to access HIV
services less frequently than females in sub-Saharan Africa
[9,13]. The greater majority of our adolescent patients were
female with many engaging in care during pregnancy. This has
been thought to be partially due to the successful expansion
of national PMTCT programs, with adolescent females being
supported and encouraged to access services and be tested
for HIV during pregnancy; hence presenting at an earlier
stage of disease. However, there may be more generalized
barriers to access and adherence that specifically affect males,
such as community stigmatization of health-seeking behavior,
reputational damage for those seeking HIV testing and treat-
ment, social norms surrounding HIV status disclosure and
clinic opening hours conflicting with hours of employment are
reported by males in qualitative investigation [25-28]. Higher
mortality among males who have never sought care has been
more recently highlighted [9]. Delays to presentation to ser-
vices may significantly impact survival among males once
treatment is started. Expansion of national programming to
specifically address the intersection of SDG5 and SDG3
concerns, may seek to remove barriers for adolescent male
attendance and retention within HIV care and treatment pro-
grammes and assist in altering community perception to
achieve cultural normalization of male health-seeking behavior
among adolescents living with HIV [27].
Within the context of an integrating framework of SDGs,
leveraging the educational sector could facilitate changes
within primary and secondary education to improve adoles-
cent male knowledge and attitudes towards health (SDG4.1-
4.7). Demonstrating links between the health of males of sexu-
ally active ages and consequent economic productivity, both
through the education sector (SDG4.1-4.7) and employment
sector (SDG8.1-8.6) could further highlight opportunities for
intervention. Integrating SDG approaches may ultimately allow
for greater alignment of intersectoral efforts in achieving the
unifying objective of improved control of and response to the
HIV epidemic for children and adolescents living with HIV.
Overall SDG3 and SDG5 indicator findings point to a num-
ber of key stages of life during which more rigorous attention
to age- and gender-specific needs may render significant ben-
efits. Adolescents living with HIV remain particularly vulnera-
ble to health inequity within HIV services, experiencing
greater non-adherence, loss to follow-up and higher cumula-
tive risk of death, than across other age categories. Those
who enroled in care in early adolescence within our cohort
had the highest cumulative mortality overall, across the age
groups, with males having higher cumulative risk of death
across every age group. Paediatric and early adolescent
patients within our cohort may have been the most likely to
have been perinatally infected, representing particularly high-
risk groups (although age at enrolment can offer only a crude
indicator of timing of infection). Higher cumulative risk of
death among those enrolled during early adolescence, may
point to longer duration of perinatally acquired HIV infection
and shortcomings in management of earlier infection. More
rigorous attention to testing and linkage to care for children
affected by HIV in early life, or loss of retention within care,
during earlier childhood may reduce the impacts on mortality
in early life [2,3,15,16]. Those enrolling in early adolescence
may have experienced a lack of sustained management of
their disease, or a repeated number of enrolments across dif-
ferent HIV services. Strengthening linkages for testing and
treatment of infants once mothers are enrolled in PMTCT,
and continued engagement with children once born within
PMTCT programmes may diminish losses in continuity of care,
that may be worsening the survival of perinatally infected chil-
dren. The second highest cumulative risk of death, according
to age group, was found among late adolescents, who may
have been more likely to be sexually infected. Hence, later
ART initiation, loss to follow-up and worse non-adherence in
late adolescence, may lead to greater cumulative risk of death
with age during adolescence. Hence, interventions supporting
focused engagement, adherence and retention, within care,
could save many years of life for adolescents living with HIV
in sub-Saharan Africa [15,16]. Strategies for improving ser-
vices for adolescents have been described [27]. Tanzania has
made significant progress in incorporating evidence within
national strategies for mapping HIV service delivery strategies
for adolescents [27,28]. National efforts may be additionally
better substantiated by incorporation of integrating SDG
frameworks in the future.
SDG5 was implicated in our findings with females in late
adolescence being more likely to experience delayed ART initi-
ation. Many of the adolescent girls in our cohort were preg-
nant at enrolment, representing an important time during
which adolescent girls access services. Adolescent females
may generally present at an earlier disease stage during a
high-risk period of sexual reproductive life. However, a lack of
integration of sexual and reproductive health services within
HIV services (SDG 3.7) may lead to discrimination against
women and girls in sub-Saharan Africa [30,31]. Adolescent
girls are vulnerable to sexually transmitted infections and
require access to effective sexual, reproductive and HIV
health services. High quality sexual and reproductive health
services may mitigate incident HIV infections and unwanted
pregnancies among adolescents (SDGs 3.3, 3.7, 3.8) [7]. Fail-
ings in services for both adolescent males and females have
important consequences for the fulfillment of SDG 3.8, limit-
ing the achievement of effective universal health coverage,
financial risk protection and access to quality essential health
care services and medicines.
SDG3 indicators utilized in this analysis may have formed
proxy indication of most likely mode of transmission, given
that paediatric and early adolescent infections were more
likely to have been perinatally transmitted and late adolescent
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infections were more likely to have been sexually transmitted.
These limitations are usual to data from clinical cohorts, as
engagement with clinical services relies on prevailing social
and cultural norms concerning health-seeking behaviors. Fur-
ther measures for appraising SDG3, SDG5 and related SDG
targets may be incorporated into future studies. Gains in
health from application of integrating SDG framework
approach to programme management, monitoring and evalua-
tion could also be demonstrated in future research work.
While studies from enrollees within HIV treatment services in
sub-Saharan African countries are becoming increasingly avail-
able, population-based sampling is ideally needed for a more
accurate estimation of population health [8, 9]. Sampling only
from sites of clinical care may lead to misclassification and
measurement error [9, 31]. For instance, those who die in
childhood following maternal transmission of infection and
those who are lost to follow-up are unlikely to be reported or
confirmed as dead. Limits to national systems of health-related
data collection limit the potential for fulfillment of SDG 17.18
(data monitoring and accountability) to track progress made in
expanding treatment for HIV [15].
Despite the widespread expansion of ART treatment, further
action is required to improve access to care and retention
within health services [13-17]. Additionally, emphasis is
required on community and structural factors, which lead to
poor health outcomes for this population, such as gender
power inequity, stigma, poverty and lack of other resources
needed to access care [32-35]. A holistic approach to the well-
being of children and adolescents affected by HIV in sub-
Saharan Africa is needed to prevent failure of efforts to
achieve the SDGs. Failings in fulfillment of SDG3 for HIV-
infected children and adolescents in sub-Saharan Africa have
implications for the fulfillment of several further SDGs, includ-
ing SD4 (the commitment to inclusive and equitable quality
education for all) and multiple aspects of SDG8 (sustained,
inclusive and sustainable economic growth, full and productive
employment and decent work for all). HIV-infected adolescent
males are experiencing higher cumulative risk of death and
reductions in life expectancy [8,9], preventing their primary
and secondary education (impacting SDGs 4.1-4.7) and contri-
bution to the sustained economic growth of the nation (impact-
ing SDGs 8.1.1, 8.2.1, 8.3.1, 8.5 and 8.6) [29]. Well-developed
national commitments to the fulfillment of SDG 8b (to develop
and operationalize a global strategy for youth employment)
must recognize the impact of the HIV epidemic on adolescent
lives. Strategies to improve adolescent engagement with and
adherence and retention within HIV-treatment programmes
are necessary to mitigate the inter-related failure of SDGs 3, 4
and 8 and the subsequent failure of SDG 10 (the reduction in
inequality within and among countries).
Our data highlight important equity concerns for children
and adolescents seeking HIV treatment and care services in
sub-Saharan Africa. Threats to the fulfillment of Sustainability
Development Goals (SDGs) concerning health for all ages
(SDG3), gender equality (SDG5), education (SDG4) and eco-
nomic growth (SDG8) are highlighted by this study. Further
downstream consequences of failed attempts to effectively
treat and care for HIV-infected children and adolescents
within sub-Saharan African health services would additionally
undermine efforts to reduce inequalities within and among
countries (SDG10). Efforts to improve national systems of
data monitoring and accountability (SDG17) need to incorpo-
rate the measurement of the health of children and adoles-
cents living with HIV, within integrating SDG frameworks
in the future, to realize maximum benefits for population
governance.
5 | CONCLUSION
Strengthening health services for HIV-infected children and
adolescents in sub-Saharan Africa will require special attention
to age and gender inequities for fulfillment of the SDGs by
2030.
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